Exiqon, a provider of technologies for biomarker detection, has introduced Good Laboratory Practice (GLP) compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.
The addition to Exiqon’s product offering allows the company to further exploit its position as the miRNA company to deliver customized contract research services for clinical research and companion diagnostic programs to its partners based on Exiqon’s LNA detection technology and miRNA biomarkers.
Exiqon can provide a full suite of services to support miRNA biomarker diagnostic programs in both clinical FFPE tissue as well as bio fluids.
Exiqon provides complete project design, samples isolation and processing and biomarker analysis using Exiqon’s LNA technology.
Exiqon also provides bioinformatics packages to support technical development and interpretation of biomarker data.
Diagnostics and Pharma Services director Adam Baker said that this clinical partnering service capability is a natural complement to their internal diagnostic programs and harness all the processes and infrastructure they have developed to drive their own diagnostics pipeline.